Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Safi advancing manufactured human RBC (mRBC) program for acute bleeding and chronic transfusion indications This DoD award acceler ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

The drugs show pharma at its best and its worst: drugs such as Vertex's ... the majority of FDA expert sentiment being against it, and such was the case with Sprout Pharmaceuticals' Addyi ...

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

The U.S. Food and Drug Administration said last week it approved Vertex Pharmaceuticals’ Journavx for short-term ... Wall Street for its ambitious drug pipeline that involves winning FDA approval for ...

It later moved into medicines, commercialising aspirin around the turn of the 20th century, one of the most successful pharmaceuticals ... and Drug Administration (FDA) rules demanding proof ...

New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug research and delay FDA approvals.

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...